Reported 4 months ago
The article discusses how Eli Lilly and Novo Nordisk could be the top-performing pharmaceutical stocks through 2030. Both companies are leaders in the diabetes and obesity treatment markets, with innovative medicines like Mounjaro and Ozempic driving revenue growth. Despite competition, their diversified portfolios and promising pipelines position them well for continued success in the industry. With strong financial results and market performances, Eli Lilly and Novo Nordisk are seen as potential trillion-dollar stocks by 2030.
Source: YAHOO